JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report) today and set a price target of $36.00. The company’s shares closed last Thursday at $6.52, close to its 52-week low of $5.00.
According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 6.3% and a 37.3% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
Currently, the analyst consensus on Taysha Gene Therapies is a Strong Buy with an average price target of $40.50, representing a 558.5% upside. In a report issued on March 29, BTIG also assigned a Buy rating to the stock with a $44.00 price target.
The company has a one-year high of $27.00 and a one-year low of $5.00. Currently, Taysha Gene Therapies has an average volume of 216.1K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Read More on TSHA:
- Papa John’s International (PZZA) Gets a Buy Rating from BTIG
- BTIG Maintains Their Buy Rating on Verra Mobility (VRRM)
- BTIG Believes CTI BioPharma (CTIC) Won’t Stop Here
- Galaxy Digital Holdings (BRPHF) Gets a Buy Rating from BTIG
- Analysts Offer Insights on Technology Companies: Unity Software (U) and Sharecare (SHCR)